123
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Glutamate Acts as a Key Signal Linking Glucose Metabolism to Incretin/cAMP Action to Amplify Insulin Secretion

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Incretins, hormones released by the gut after meal ingestion, are essential for maintaining systemic glucose homeostasis by stimulating insulin secretion. The effect of incretins on insulin secretion occurs only at elevated glucose concentrations and is mediated by cAMP signaling, but the mechanism linking glucose metabolism and cAMP action in insulin secretion is unknown. We show here, using a metabolomics-based approach, that cytosolic glutamate derived from the malate-aspartate shuttle upon glucose stimulation underlies the stimulatory effect of incretins and that glutamate uptake into insulin granules mediated by cAMP/PKA signaling amplifies insulin release. Glutamate production is diminished in an incretin-unresponsive, insulin-secreting β cell line and pancreatic islets of animal models of human diabetes and obesity. Conversely, a membrane-permeable glutamate precursor restores amplification of insulin secretion in these models. Thus, cytosolic glutamate represents the elusive link between glucose metabolism and cAMP action in incretin-induced insulin secretion.

          Graphical Abstract

          Highlights

          • Glutamate is derived from the malate-aspartate shuttle upon glucose stimulation

          • Shuttle-derived glutamate is crucial for incretin-induced insulin secretion

          • Cytosolic glutamate is transported into insulin granules via cAMP/PKA signaling

          • Glutamate production by glucose is defective in incretin-unresponsive β cells

          Abstract

          Gheni et al. find that cytosolic glutamate derived from glucose through the malate-aspartate shuttle is the signal underlying incretin-induced insulin secretion. Glutamate uptake into insulin granules mediated by cAMP/PKA signaling amplifies insulin release. Thus, cytosolic glutamate acts as a signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: not found

          The biology of incretin hormones.

          Gut peptides, exemplified by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted in a nutrient-dependent manner and stimulate glucose-dependent insulin secretion. Both GIP and GLP-1 also promote beta cell proliferation and inhibit apoptosis, leading to expansion of beta cell mass. GLP-1, but not GIP, controls glycemia via additional actions on glucose sensors, inhibition of gastric emptying, food intake and glucagon secretion. Furthermore, GLP-1, unlike GIP, potently stimulates insulin secretion and reduces blood glucose in human subjects with type 2 diabetes. This article summarizes current concepts of incretin action and highlights the potential therapeutic utility of GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

            In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) and in nine age- and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dose-dependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Glucagon-like peptide-1 7-36: a physiological incretin in man.

              The physiological role of glucagon-like peptide-1 7-36 amide (GLP-1 7-36) in man was investigated. GLP-1 7-36-like immunoreactivity was found in the human bowel; its circulating level rose after oral glucose and after a test breakfast. When it was infused into seven volunteers at a rate to mimic its postprandial plasma concentration in the fasting state, plasma insulin levels rose significantly and glucose and glucagon concentrations fell. During an intravenous glucose load, it greatly enhanced insulin release and significantly reduced peak plasma glucose concentrations, compared with a control saline infusion, even inducing postinfusion reactive hypoglycaemia. By comparison, infusion of glucose-dependent insulinotropic peptide (GIP) to physiological levels was less effective in stimulating insulin release. These observations suggest that GLP-1 7-36 is a physiological incretin and that it is more powerful than GIP. The observation of greatly increased postprandial plasma GLP-1 7-36 levels in patients with postgastrectomy dumping syndrome suggests that it may mediate the hyperinsulinaemia and reactive hypoglycaemia of this disorder.
                Bookmark

                Author and article information

                Contributors
                Journal
                Cell Rep
                Cell Rep
                Cell Reports
                Cell Press
                2211-1247
                16 October 2014
                23 October 2014
                16 October 2014
                : 9
                : 2
                : 661-673
                Affiliations
                [1 ]Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017, Japan
                [2 ]Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017, Japan
                [3 ]Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017, Japan
                [4 ]The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017, Japan
                [5 ]Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606–8507, Japan
                [6 ]Department of Biotechnology, Graduate School of Engineering, Osaka University, Yamadaoka, Suita 565-0871, Japan
                [7 ]Applied Environmental Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Yamadaoka, Suita 565-0871, Japan
                [8 ]Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
                [9 ]Alberta Diabetes Institute, University of Alberta, Faculty of Medicine & Dentistry, Edmonton, AB T6G 2E1, Canada
                [10 ]Department of Neural Regeneration and Cell Communication, Mie University Graduate School of Medicine, Edobashi, Tsu 514-8507, Japan
                [11 ]Life Science Research Center, Technology Research Laboratory, Shimadzu Corporation, Soraku-gun, Kyoto 619-0237, Japan
                Author notes
                []Corresponding author seino@ 123456med.kobe-u.ac.jp
                [12]

                Co-first author

                [13]

                Present address: Division of Metabolism and Clinical Nutrition, Kansai Electric Power Hospital, Fukushima-ku, Osaka 553-0003, Japan

                Article
                S2211-1247(14)00813-4
                10.1016/j.celrep.2014.09.030
                4536302
                25373904
                10bb7b24-dc3f-454c-a283-c039f523fd18
                © 2014 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).

                History
                : 13 February 2014
                : 19 August 2014
                : 15 September 2014
                Categories
                Article

                Cell biology
                Cell biology

                Comments

                Comment on this article